Kornimate/medical-research-clean huggingface dataset:
impact of hemodialysis on exhaled volatile organic compounds in end stage renal disease

Conditions: End Stage Renal Disease

Summary: end stage renal disease (esrd) is a severe clinical state of irreversible loss of endogenous kidney function, shortening life expectancy, if left untreated. in the state of esrd, over 5000 uremic toxins are accumulated in the body causing dysfunction of various organ systems. the survival of these patients depends on renal replacement therapies, such as hemodialysis (hd), which artificially purifies the blood from toxins. the investigators assume that some of the uremic toxins are also present in the patient's exhaled breath, and could be detected by a non-invasive and highly sensitive test: a na-nose artificial olfactory system. it is based on analysis of volatile organic compounds (vocs), a novel, non-invasive field in medical diagnostics. the na-nose is made from an array of nanosensors, and was developed by our collaborator dr. hossam haick (chemical engineering, technion). in the current study, the investigators utilize this technology to identify vocs in the exhaled breath of dialysis patients, and to characterize certain patterns of expression that could potentially help in future monitoring of hd adequacy. the investigators plan to collect 150 breath samples from patients before and during dialysis, and from healthy subjects. all participants provide a signed informed consent. subsequently, analysis of samples will be done at dr. haick's laboratory, using gas-chromatography/mass-spectrometry and parameters extracted from each sensor response.


Eligibility criteria:
inclusion criteria: * 18 years and older * end stage renal disease receiving hemodialysis exclusion criteria: * age under 18 * pregnancy * malignancy * infectious diseases

Keywords: end stage renal disease hemodialysis breath test volatile organic compound dialysis adequacy
a phase i/ii study of cr011-vcmmae in subjects with unresectable stage iii or stage iv melanoma

Conditions: Unresectable Stage III or Stage IV Melanoma

Summary: this study will evaluate the safety, tolerability and pharmacokinetics of cr011-vcmmae in patients who have unresectable stage iii or stage iv melanoma and have failed no more than 1 line of prior cytotoxic therapy. cr011-vcmmae will be administered intravenously (iv) once every 3 weeks at escalating doses until the maximum tolerated dose (mtd) is reached. once the mtd is defined, 18-32 patients will be enrolled to further evaluate the safety and efficacy of cr011-vcmmae at this dose level. additional dosing schedules of cr011-vcmmae will also be explored.


Eligibility criteria:
inclusion criteria: * male or female with age ≥ 18 years. * progressive or new metastatic melanoma, stage iii or iv. * measurable disease by ct / mri * failure of no more than 1 line of prior cytotoxic therapy. * adequate bone marrow, renal and hepatic function * leukocytes ≥ 3000/mm3, anc ≥ 1,500 cells/mm3, platelets ≥ 100,000/mm3 * hemoglobin ≥ 10 g/dl (transfusion allowed) * total bilirubin ≤ 1.5 x upper normal limit (unl) * ast (sgot), alt (sgpt) ≤ 3.0 x unl (≤ 5.0 x unl may be acceptable) * serum creatinine ≤ 1.5 mg/dl or calculated creatinine clearance \> 45 ml/min/1.73 m2 * pt/aptt \< 1.5 x unl or within therapeutic range via anti-coagulation therapy * karnofsky ps ≥ 70%. * estimated life expectancy \> 3 months. * signed informed consent approved irb and ability to comply with the study or monitoring procedures. * subjects with evaluable disease are eligible in dose-escalation cohorts exclusion criteria: * prior therapies for disease under study less than 4 weeks prior to enrollment. * major surgery or trauma within 4 weeks of enrollment. * active brain metastases * active chronic inflammatory, autoimmunity, immunodeficiency disease, and vascular or hemorrhagic disorders. * history of allergic reactions to dolastatin, auristatin or compounds of similar composition. * significant cardiovascular disease * other malignancies * pregnancy or breast feeding * refusal or inability to use effective means of contraception (for men, and women with childbearing potential) * history of or test-positive to hiv, or hepatitis b or c

Keywords: melanoma cr011-vcmmae
efficacy of magnetic stimulation for stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the aim of the study is to investigate the effects of qrs®-1010 pelvicenter in female patients with stress urinary incontinence. based on the available data on magnetic stimulation, the investigators hypothesize that magnetic stimulation via qrs®-1010 pelvicenter will reduce the number and amount of urinary leakage upon exertion as well as improve patients' quality of life.

a total of 120 female patients will be randomly assigned into two treatment groups (active arm and sham arm) in a 1:1 ratio. the standard qrs®-1010 pelvicenter treatment plan involves 16 sessions of 20 minutes each. each subject will attend 2 sessions per week (total 16 sessions).

Eligibility criteria:
inclusion criteria: * female aged at least 21 years old * demonstration of stress urinary incontinence by vaginal examination with half full bladder (200 to 250ml) * iciq ui sf score ≥ 6 points * able and agree to carry out one hour pad test exclusion criteria: * acute severe infections * urinary tract infections and hematuria, active vaginal lesions or infections * pelvic organ prolapse stage iii and iv, severe urethral sphincter weakness/defect, suspected fistula * severe cardiac arrhythmia * cardiac pacemaker or other implanted metallic devices * history of pelvic irradiation * pregnant, or actively trying to conceive. * neurologic conditions such as epilepsy, parkinson disease, multiple sclerosis * patient who has been treated with electromagnetic stimulation * concurrent medications with alpha-adrenergic antagonists (e.g. terazosin, tamsulosin, doxazosin), diuretics, serotonin/norepinephrine reuptake inhibitors (snris) or any other medications known to worsen incontinence. * post void residual volume of ≥ 200ml * random blood sugar \>10 mmol/l * patient who had pelvic or gynaecological surgery for less than three weeks * patient scheduled for pelvic or gynaecological surgery in the next eight weeks
cuhk jockey club hope 4 care programme - ankle robot

Conditions: Stroke

Summary: the hong kong jockey club charities trust has supported cuhk to launch a three-year project 'cuhk jockey club hope4care programme' to implement four evidence-based advanced rehabilitation technologies in 40 local elderly day care centres and rehabilitation centres, to benefit the community. the exoskeleton ankle robot is a robot-assisted ankle-foot-orthosis to facilitate gait training of person after stroke with drop foot.


Eligibility criteria:
inclusion criteria: * have the ability to walk on the ground independently or with one personal assistance with or without walking aids * able to understand simple commends exclusion criteria: * have other neurological, neuromuscular, and orthopedic diseases * uncontrolled cardiovascular or respiratory disorders * moderate to severe contractures in the lower extremities
endothelin receptor blockade in acute st-elevation myocardial infarction

Conditions: ST-Elevation Myocardial Infarction

Summary: background and objective: acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. the aim of the present study is to investigate the effect of et-receptor blockade by bq-123 on myocardial perfusion and infarct size as an adjunct to pci-reperfusion therapy in patients with stemi. patients are randomized to receive periinterventional intravenous bq-123 or placebo.

background and objective: acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. we have previously shown that thrombectomy in st-elevation myocardial infarction (stemi) accelerates st-segment resolution, possibly by preventing distal embolization. therefore, we analyzed the vasoconstrictor concentration of acute coronary thrombi, and found high concentrations of endothelin (et) which correlated with the magnitude of st-segment resolution within one hour of percutaneous coronary intervention (pci). furthermore, et-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from stemi patients. the aim of the present study is to investigate the effect of et-receptor blockade by bq-123 on myocardial perfusion and infarct size as an adjunct to pci-reperfusion therapy in patients with stemi. methods: fifty eligible patients will be randomized to receive periinterventional intravenous bq-123 or placebo. the primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography.

Eligibility criteria:
inclusion criteria: * stemi patients (defined as: evidence of ischemic chest pain for \>30 minutes within \ 1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-t), aged 18 years and above, who undergo primary percutaneous revascularization (pci) and have confirmed initial timi 0 or 1 in the infarct related coronary artery. exclusion criteria: * significant liver disease * thrombolytic therapy * history of prior myocardial infarction * current atrial fibrillation * history of congestive heart failure * history of migraine headache * significant valvular heart disease, primary myocardial disease * cardiogenic shock (srr \<90mmhg or need for inotropic support) * child-bearing potential * inability to read, understand and sign the informed consent * life expectancy \<3y * prior organ transplantation * medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives * participation in another clinical study * metal implants contraindicating cmr

Keywords: infarction endothelin perfusion
human lung responses to respiratory pathogens

Conditions: Respiratory Infection

Summary: for most individuals, the lung has a remarkable ability to deal with exposure to a variety of inhaled bacteria. some individuals, however, do have recurrent bacterial infections, usually in the form of acute or chronic bronchitis and, in some instances, pneumonia. the reasons for this variability in bacterial infections between otherwise healthy subjects, between types of lung disease, and within the same type of lung disease are poorly understood. variability in susceptibility to bacterial infections is partially explained by differences in exposure to infectious agents, genetic susceptibility and innate (or early) immune responses. it is of interest that the incidence and severity of bacterial infections is greatest during the winter months. other than viral infections, there are few variables that change with season. vitamin d is one known immune modulator with a seasonal periodicity. the hypothesis of this study is that levels of vitamin d are an important determinant of the innate defense of the lung against inhaled bacteria. the investigators further postulate that vitamin d has effects on the innate immune function of both alveolar macrophages and lung epithelial cells.


Eligibility criteria:
inclusion criteria: signed informed consent form age 18 - 60 healthy nonsmoker, healthy smoker forced expiratory volume in 1 second (for smokers) \> 60% predicted. exclusion criteria: * pregnant or breastfeeding * medications (with the exception of hormonal birth control, thyroid medication or prespecified over the counter medications), including multi-vitamins and any preparation that contains vitamin d * asthma * heart disease * diabetes * previous positive tuberculin skin test, or previous diagnosis of tuberculosis * recent respiratory tract infection * history of multiple bouts of pneumonia * allergies to caines, atropine, or a history of adverse reaction to narcotics * other factors that increase the risk of bronchoscopy * evidence of acute bronchitis within the past 2 weeks

Keywords: vitamin d respiratory infection innate immunity
evaluation of behaviour in parkinson's disease. normal values in healthy subjects

Conditions: Behaviour

Summary: non-motor symptoms like mood fluctuations and behavioral disorders are frequent in parkinson's disease. they may be induced by both the pathology and the dopaminergic treatment and must be considered in treatment policies. due to their specificity and the absence of an appropriate evaluation tool, behavioral disorders are rarely searched for. therefore, investigators developed a scale permitting qualitative and quantitative evaluation of behavior according to the severity of the disorders. this study aims to define reference values for healthy individuals

the application of the scale includes a semi-structured interview the ecmp scale consists of 21 items, each of which may be assessed by use of a 5 point scale (not at all - light trouble - moderate trouble - important trouble - severe trouble)

Eligibility criteria:
inclusion criteria: * healthy participants without any neurologic disease * men and women from 25 to 75 years old * french mother tong * without cognitive troubles (mms ≥ 24) exclusion criteria: * subject under legal guardianship * pregnant woman or with childbearing potential without contraceptive device
ultraviolet b (uvb) light therapy in the treatment of skin conditions with altered dermal matrix

Conditions: Keloid; Scleroderma, Localized; Acne Keloidalis; Scars; Granuloma Annulare

Summary: this research study will evaluate the effectiveness of high dose uvb light therapy in the treatment of keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, granuloma annulare or related conditions.

keloid, scleroderma, acne keloidalis nuchae, and burn scars are all characterized by collagenous thickening of the skin resulting in superficial and deep cutaneous sclerosis. treatments for these disabling conditions are inadequate at present. recently, in non-controlled studies, uva1 was shown to induce improvement in patients with scleroderma, granuloma annulare and urticaria pigmentosa. however, uva1 is unable to penetrate pigmented skin at an effective level to activate matrix metalloproteinases (mmps). the investigators' preliminary data show that high dose uvb (160 mj/cm2) will penetrate pigmented skin and activate the cellular pathways necessary to stimulate mmps. they postulate, therefore, that in pigmented skin, higher than usual uvb doses can improve these fibrosing skin conditions safely through collagenase-mediated removal of excess dermal collagen via activation of mmp pathways. the purpose of this research project is to study the effectiveness of high dose uvb (290-320nm at up to 320mj/cm2) irradiation for the treatment of skin conditions with altered dermal matrix in patients with increased skin pigmentation. these disorders include but are not limited to keloid (or hypertrophic scar), scleroderma, acne keloidalis nuchae, old burn scars, and granuloma annulare. up to fifty patients with one of these diagnoses or related conditions will receive uvb irradiation up to 5 times per week, for 16 weeks.

Eligibility criteria:
inclusion criteria: * in good general health and between 10-80 years of age. * willing and able to receive uvb, as directed in the protocol; make evaluation visits; follow protocol restrictions; and sign a written, witnessed, informed consent form. * have a clinical diagnosis of keloid, scleroderma, old burn scars, granuloma annulare, or acne keloidalis nuchae. * no disease states or physical conditions that would impair evaluation of the test site * must live within a reasonable driving distance of ann arbor, michigan, and/or be able to attend all of the scheduled appointments during the study. exclusion criteria: * have a history of photosensitivity (development of hives or bumps with exposure to light) or experience hypersensitivity in a uvb photo-provocation test. * have participated in another investigational study in the past 4 weeks, taken oral therapy for skin condition, or on photosensitizing medications. * pregnant, nursing, or planning to become pregnant during the study.

Keywords: uvb keloid scleroderma acne keloidalis nuchae scars granuloma annulare
a prospective study to investigate safety and tolerability of shorter infusion of fabrazyme

Conditions: Fabry's Disease

Summary: this phase 4 study will evaluate the safety and tolerability of fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. this study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with fabrazyme.

the total duration will be up to 7 months

Eligibility criteria:
inclusion criteria: - participants with confirmed diagnosis of fd who are ≥2 and ≤65 years of age at the time of signing the informed consent form (icf) or assent, if applicable. * cohort 1: female participants with body weight ≥30 kg who have been treated with fabrazyme for at least 3 months without iars during the most recent 3 infusions. * cohort 2: non-classic male participants with body weight ≥30 kg who have been treated with fabrazyme for at least 3 months without iars during the most recent 3 infusions. * cohort 3: classic male participants with body weight ≥30 kg who have been treated with fabrazyme for at least 3 months without iars during the most recent 3 infusions. * cohort 4: participants with body weight \<30 kg who have been treated with fabrazyme for at least 3 months without iars during the most recent 3 infusions. women of childbearing potential must use a highly effective method of contraception through the study. exclusion criteria: * female participants who are pregnant or breastfeeding. * history of significant allergic disease or hypersensitivity to fabrazyme or other medicinal products. * contraindication to fabrazyme or any of the premedications or rescue medications (diphenhydramine, loratadine, cetirizine, fexofenadine, acetaminophen, montelukast, dexamethasone). * any other medical condition considered to make the increased infusion rate not tolerable at the investigator's discretion. the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
the effect of chimeric antigen receptor (car)-t cell therapy on the reconstitution of hiv-specific immune function

Conditions: HIV/AIDS

Summary: to study the safety and effectiveness of car-t cell therapy on hiv patients whose plasma hiv has been successfully suppressed after cart, which is expected to enhance the res-constitution of hiv-specific immune function to assist the eradication of hiv reservoir.

despite the advent of combined antiretroviral therapy (cart), the persistence of viral reservoirs remains a major barrier to curing human immunodeficiency virus type 1 (hiv-1) infection. recently, the shock and kill strategy, by which hiv-1 reservoirs could be eradicated following reactivation of latent hiv-1 by latency-reversing agents (lras), has been extensively practiced. it is important to reestablish virus-specific and reliable immune surveillance to eradicate the reactivated virus-harboring cells.the vc-car-t cells effectively induced the cytolysis of lra-reactivated hiv-1-infected cd4 t lymphocytes isolated from infected individuals receiving successful cart. our previous study demonstrated that the special features of genetically engineered car-t cells make them a particularly suitable candidate for therapeutic application in efforts to reach a functional hiv cure. in this clinical trial, we intend to study the safety and effectiveness of car-t cell therapy on hiv patients whose plasma hiv has been successfully suppressed after cart, by observing the adverse events, hiv-1 reservoir and the immune index.

Eligibility criteria:
inclusion criteria: 1. hiv infection confirmed. 2. receiving cart more than 12 months. 3. hiv viral-load \< 50 copies/ml and cd4 cell count more than 350 cells/ul. 4. without serious liver, heart, liver and kidney diseases. 5. the subjects know about the study and volunteer to attend the research and sign the informed consent. exclusion criteria: 1. with active hbv or hcv infection, or serious opportunistic infections. 2. with serious chronic disease such like diabetes, the mental illness,et al 3. history of suffering from pancreatitis during cart. 4. pregnant or breast-fed. 5. with poor adherence. 6. unable to complete follow up.

Keywords: car-t hiv therapy immunotherapy function cure
sistas informing sistas on topics about aids and prevention (sista-p)

Conditions: Health Behavior, Risky; Health Knowledge, Attitudes, Practice; Health-Related Behavior

Summary: in this project, the investigators will provide a new hiv prevention training and empowerment sessions to black women in washington d.c. who are at high risk for getting hiv. this training is tailored to the experience of black women and seeks to reduce the high hiv transmission rates in the black community.

experienced facilitators will implement two cycles of six 3-hour sessions with up to 15 participants per cycle while expert panelists observe. after each session, participants and subject matter expert observers will complete brief surveys. surveys following each session include closed and open-ended measures: six items rating how well the session conveyed core information (e.g., i am confident i can communicate more effectively \[session 3\]; i have a better understanding of the effects of alcohol on making sexual choices, \[session 4\]) and single-item scales to evaluate the facilitator's performance and the session overall. in open-ended measures, respondents will be prompted to elaborate on their survey responses to identify ways the session could be improved.

Eligibility criteria:
inclusion criteria: * black women are eligible if you: * have sex with men * are age 18+ * live in washington d.c. * are not hiv+ exclusion criteria: * hiv+

Keywords: black women hiv
can habitus adapted length based body weight estimation be improved by adding further parameters?

Conditions: Weight-Estimation

Summary: the purpose of this prospective single center study is to investigate if the accuracy of length based body weight estimation by the already investigated algorithm (clawar) can be improved by adding another parameter. for this study 500 patients are required to collect anonymized data (length, weight, age, mid upperarm circumference and patient habitus by visual estimation) for achieving a power of 80% during statistical analysis. the main hypothesis ist that clawar's accuracy can be improved.

this prospective single center study is performed at the university children's hospital zurich. patients planned for surgery in general anaesthesia with intubation, aged 0 to 16 years and with a body length suitable for clawar. patient and parental information is performed during the pre-anaesthetic visit. after written consent the patient will be included. patient ́s length and weight will be measures earliest one day before data collection. data collection during anaesthesia has no influence on the daily anaesthesia routine and has no impact on patient safety and anaesthesia. patient's data is made anonymous for further inspection. data is documented in microsoft excel and statistical analysis calculated with spss. 500 patients are needed for a power of 80%. primary outcome parameter is the accuracy of length based weight estimation using either patient habitus by visual estimation or an improved version of the algorithm clawar using the mid upperarm circumference.

Eligibility criteria:
inclusion criteria: * body length suitable with the investigated algorithm * all patients aged 0 -16 years exclusion criteria: * already included in this study once * missing patient or parental consent

Keywords: anaesthesia anthropometry body weight and measures development emergency treatment patient safety